Tullis Health Investors
VC Fund
Stamford, United States
Tullis Health Investors is a private equity group that invests primarily in the healthcare sector.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Tullis Health Investors invests in
Health CareBiotechnologyMedicalTherapeuticsMedical Device
Stages Tullis Health Investors invests in
Series BSeries CFunding RoundSeries ASeries D
Countries Tullis Health Investors invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
James Tullis
|
|||
Cornelius T. Ryan
|
|||
Daisy Zhang
|
|||
Darlene Franzé
|
|||
John Tullis
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 8 (50%)
- Biotechnology 6 (38%)
- Medical 4 (25%)
- Therapeutics 4 (25%)
- Medical Device 2 (13%)
Stage
- Series B 4 (25%)
- Series C 4 (25%)
- Funding Round 3 (19%)
- Series A 2 (13%)
- Series D 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
James Tullis
Founder and CEO
|
Founder and CEO | Total investments: 1 | Find email | |
|
Cornelius T. Ryan
GP
|
GP | Total investments: 0 | Find email | |
|
Daisy Zhang
Office Manager- China
|
Office Manager- China | Total investments: 0 | Find email | |
|
Darlene Franzé
Vice President- Administration
|
Vice President- Administration | Total investments: 0 | Find email | |
|
John Tullis
Partner & Chief Executive Officer
|
Partner & Chief Executive Officer | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TriSalus Life Sciences
|
Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue. | $15M / Series C / Dec 02, 2015 | |
CareSync
|
CareSync is the leading provider of software and services for chronic disease management, combining technology with 24/7 nursing services to facilitate care coordination among patients, family and caregivers and all providers. CareSync provides turnkey Chronic Care Management services and a software-only option, allowing practices of anysize to easily meet the billing requirements for CPT code 99490. Additionally, CareSync’s certified technology makes it simple for providers to meet Meaningful Use 2 for Data Exchange, Messaging, and Timely Access. CareSync patients are at the center of their healthcare, with access to health information, actionable goals, and Comprehensive Care Plan tasks, and as a result, are experiencing more productive medical appointments and better health outcomes. | $18M / Series B / Oct 07, 2015 | |
OrthoSensor
|
OrthoSensor is an early-stage medical device company focused on developing and integrating advanced sensor technology in the Orthopedic field. The company is building a portfolio of intelligent, accurate, low-cost, and easy to use products that will extend from the operating room into the lifecycle of the implanted orthopedic device. Itsintelligent orthopedic devices utilize advanced proprietary sensor and communications technologies, coupled with the company’s innovative software products, to facilitate evidence-based decisions in orthopedic surgery – with the goal of improving patient outcomes and potentially reducing the cost of treating musculoskeletal disease. It was founded in 2006 and is headquartered in Dania, Florida. | $19M / Series C / Mar 23, 2015 | |
Exagen
|
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based onour proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.Exagen was established in 2002 and is headquartered in Vista, California. | $25M / Debt Financing / Nov 04, 2013 | |
|
Exagen
|
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE brand, several of which are based onour proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen’s goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus.Exagen was established in 2002 and is headquartered in Vista, California. | $16.9M / Feb 25, 2011 | |
BioBehavioral Diagnostics
|
BioBehavioral Diagnostics Company manufactures and markets the Quotientâ„¢ ADHD System, a tool that aids in the objective and accurate assessment of ADHD symptoms. They are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD. | $10M / Series B / Mar 17, 2010 | |
Intranasal Therapeutics
|
Ikano Therapeutics Inc., a specialty pharmaceutical company, focuses on developing nasal spray drug products. | $18M / Series B / Mar 30, 2009 | |
Atritech
|
Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology wereperformed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States. | $30M / Mar 26, 2009 | |
|
Atritech
|
Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology wereperformed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States. | $22M / Series D / Sep 06, 2007 | |
Aldagen
|
ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improvingumbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure. | $9M / Series C / Sep 01, 2007 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Medical Device Investors
11,047 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Tullis Health Investors invest in?
Tullis Health Investors invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tullis Health Investors?
Public channels for Tullis Health Investors include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tullis Health Investors?
The team at Tullis Health Investors includes James Tullis (Founder and CEO), Cornelius T. Ryan (GP) and Daisy Zhang (Office Manager- China), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
